Implications for Health and Life Insurances and Other Legal Aspects of Genetic Testing

  • Ida Ngueng Feze
  • Shahad Salman
  • Yann JolyEmail author


Scientific breakthroughs have fostered the development of new genomic tools, which are generating an unprecedented amount of genetic data. This information has been a catalyst in the transition towards personalized medicine by rapidly becoming integrated to the health care and the research settings but also through the use of direct-to-consumer genetic services. Despite the wealth of perceived benefits in improved diagnosis, treatments, and preventive measures, concerns continue to be raised about the use of genetic information for nontherapeutic purposes and genetic discrimination in the context of insurance. As various neurologists and researchers in movement disorder genetics are increasingly being solicited to assist patients to deal with these concerns, they are confronted with the changing landscape of ethical and legal issues and facing a need for additional knowledge and resources about the implications that genetics may have on the insurability of patients and their family members.


Direct-to-consumer Duty to disclose Family history Genetic discrimination Genetic testing Insurance Movement disorders 



The authors would like to thank Laura Crimi at the Centre of Genomics and Policy for her valuable assistance in the preparation of this book chapter.


  1. 1.
    Adasci v Amin (Alberta). 2013 ABCA 315. 2013.Google Scholar
  2. 2.
    American Academy of Actuaries. Risk classification in voluntary life insurance. Issue Brief. Washington D.C: Spring; 1997. p. 1–4.Google Scholar
  3. 3.
    American Medical Association Code of medical ethics, Opinion 2.135 Insurance companies and genetic information. From Accessed 20 July 2014.
  4. 4.
    Armstrong K, Weber B, FitzGerald G, Hershey J, Pauly M, Lemaire J, Subramanian K, Asch D. Life insurance and breast cancer risk assessment: adverse selection, genetic testing decisions, and discrimination. Am J Med Genet. 2003;120A:359–64.CrossRefPubMedGoogle Scholar
  5. 5.
    Audet v. Industrielle-Alliance (Quebec).. [1990] R.R.A. 500 (C.S.). 1990.Google Scholar
  6. 6.
    Baruch S, Hudson KL. Civilian and military genetics: non-discrimination policy in a post-GINA world. Am J Hum Genet. 2008;83(4):435–44.CrossRefPubMedCentralPubMedGoogle Scholar
  7. 7.
    Billings P, Khon M, De Cuevas M, Beckwith J, Alper J, Natowicz M. Discrimination as a consequence of genetic testing. Am J Hum Genet. 1992;50(3):476–82.PubMedCentralPubMedGoogle Scholar
  8. 8.
    Boddington P. The ethics and regulation of direct-to-consumer genetic testing. Genome Medicine. 2009;1(7):71.CrossRefPubMedCentralPubMedGoogle Scholar
  9. 9.
    Bombard Y, Veenstra G, Friedman JM, Creighton S, Currie L, Paulsen JS, Bottorff JL, Hayden MR, Group TCR-HCR. Perceptions of genetic discrimination among people at risk for Huntington’s disease: a cross sectional survey. BMJ. 2009;338:b2175.CrossRefPubMedCentralPubMedGoogle Scholar
  10. 10.
    Bombard Y, Palin J, Friedman JM, Veenstra G, Creighton S, Bottorff JL, Hayden MR, The Canadian Respond-HD Collaborative Research Group. Beyond the patient: the broader impact of genetic discrimination among individuals at risk of Huntington disease. Am J Med Genet. 2012;159B:217–26.CrossRefPubMedGoogle Scholar
  11. 11.
    Bombard Y, Penziner E, Suchowersky O, Guttman M, Paulsen JS, Bottorff JL, Hayden MR. Engagement with genetic discrimination: concerns and experiences in the context of Huntington Disease. Eur J Hum Genet. 2008;16:279–89.CrossRefPubMedCentralPubMedGoogle Scholar
  12. 12.
    Bower MA, McCarthy Veach P, Bartels DM, LeRoy BS. A survey of genetic counselors’ strategies for addressing ethical and professional challenges in practice. J Genet Couns. 2002;11(3):77–101.CrossRefGoogle Scholar
  13. 13.
    Bubela T, Caulfield T. Do the print media “hype” genetic research? A comparison of newspaper stories and peer-reviewed research papers. Can Med Assoc J. 2004;170(9):1399–407.CrossRefGoogle Scholar
  14. 14.
    Bunnick E, Schermer M, Janssens AC. Personal genome testing: test characteristics to clarify the. BMC Med Ethics. 2011;12:11.CrossRefGoogle Scholar
  15. 15.
    Burke W, Psatsy B. Personalized medicine in the era of genomics. JAMA J Am Med Assoc. 2007;298:1682–4.CrossRefGoogle Scholar
  16. 16.
    Canadian Life and Health Association Inc. CLHIA position statement on genetic testing. CLHIA. 2010. Online:$file/Genetic_Testing_CLHIA_Industry_Position_2010.pdf.
  17. 17.
    Cardinal G, Deschênes M. Surveying the population biobankers. In: Knoppers BM, editor. Populations and genetics – legal and socio-ethical perspectives. Leiden: Martinus Nijhoff Publishers; 2003. p. 37–94.Google Scholar
  18. 18.
    Caulfield T, Bubela T, Murdoch CJ. Myriad and the mass media: the covering of a gene patent controversy. Genet Med. 2007;9(12):850–5.CrossRefPubMedGoogle Scholar
  19. 19.
    Chen DT, Sheperd LL. Advising patients about obtaining genomic profiles. Neurol Clin Pract. 2011;1(1):5–13.CrossRefPubMedCentralPubMedGoogle Scholar
  20. 20.
    Clifton JM, VanBeuge SS, Mladenka C, Wosnik KK. The genetic information nondiscrimination act 2008: what clinicians should understand. J Am Acad Nurse Pract. 2010;22(5):246–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Council of Europe. Convention for the protection of human rights and dignity of the human being with regards to the application of biology and medicine: convention on human rights and biomedicine. vol 4.IV.1997. Oviedo: Council of Europe. 1997. Available from Last accessed 29 July 2014.
  22. 22.
    Council of Europe. Consultation document on predictivity, genetic testing and insurance. DH-BIO/INF (2012)1. 2012.Google Scholar
  23. 23.
    Dressler LG. Disclosure of research results from cancer genomic studies: state of the science. Clin Cancer Res. 2009;15:4270–6.CrossRefPubMedGoogle Scholar
  24. 24.
    Erwin C, Williams JK, Juhl AR, Mengeling M, Mills JA, Bombard Y, Hayden MR, Quaid K, Shoulson I, Taylor S, Paulsen JS. Perception, experience, and response to genetic discrimination in Huntington disease: the International RESPOND-HD Study. Am J Med Genet. 2010;153B(5):1081–93.PubMedCentralPubMedGoogle Scholar
  25. 25.
    European Society of Human Genetics. Statement of the ESHG on direct-to-consumer genetic testing for health-related purposes. Eur J Hum Genet. 2010;18(12):1272–3.Google Scholar
  26. 26.
    Investment and Financial Services Association Limited. Life insurance and genetic testing in Australia. Sydney: IFSA; 2002.Google Scholar
  27. 27.
    Freedman AN, Wideroff L, Olson L, Davis W, Klabunde C, Srinath KP, Reeve BB, Croyle RT, Ballard-Barbash R. US physicians’ attitudes toward genetic testing for cancer susceptibility. Am J Med Genet. 2003;120A(1):63–71.CrossRefPubMedGoogle Scholar
  28. 28.
    Freeman VG, Rathore SS, Weinfurt KP, Schulman KA, Sulmasy DP. Lying for patients: physicians deception of third-party payers. Arch Intern Med. 1999;159(19):2263–70.CrossRefPubMedGoogle Scholar
  29. 29.
    Frucht SJ. Movement disorder emergencies: diagnosis and treatment. In: Current clinical neurology. 2nd ed. New York: Humana Press; 2013.Google Scholar
  30. 30.
    Gasser T, Bressman S, Dürr A, Hinggins J, Klockgether T, Myers RH. Molecular diagnostic of inherited movement disorders: movement disorders society task force on molecular diagnostic. Mov Disord. 2003;18(1):3–18.CrossRefPubMedGoogle Scholar
  31. 31.
    Geelen E, Horstman K, Marcelis CL, Doevendans PA, Van Hoyweghen I. Unravelling fears of genetic discrimination: an exploratory study of Dutch HCM families in an era of genetic non-discrimination acts. Eur J Hum Genet. 2012;20:1018–23.CrossRefPubMedCentralPubMedGoogle Scholar
  32. 32.
    Genetic Information Nondiscrimination Act. United States. 2008.Google Scholar
  33. 33.
    Geppert CMA, Weiss RL. Protecting patient confidentiality in primary care. Semin Med Pract. 2000;3(1):7–14.Google Scholar
  34. 34.
    Godard B, Pratte A, Dumont M, Simard-Lebrun A, Simard J. Factors associated with an individual’s decision to withdraw from genetic testing for breast and ovarian cancer susceptibility: implications for counseling. Genet Test. 2007;11(1):45–54.CrossRefPubMedGoogle Scholar
  35. 35.
    Godard B, Raeburn S, Pembrey M, Bobrow M, Farndon P, Ayme S. Genetic information and testing in insurance and employment: technical, social and ethical issues. Eur J Hum Genet. 2003;11 Suppl 2:S123–42.CrossRefPubMedGoogle Scholar
  36. 36.
    Greendale K, Pyeritz RE. Empowering primary care heath professional in medical genetics: how soon? How fast? how far? Am J Med Genet. 2001;106(3):223–32.CrossRefPubMedGoogle Scholar
  37. 37.
    Guttmacher AE, Collins F, Carmona RH. The family history – more important than ever. New Engl J Med. 2004;351(22):2333–6.CrossRefPubMedGoogle Scholar
  38. 38.
    Guttmacher AE, Jenkins J, Uhlmann WR. Genomic medicine: who will practice it? A call to arms. Am J Med Genet. 2001;106:216–22.CrossRefPubMedGoogle Scholar
  39. 39.
    Hadley D, Jenkins J, Dimond E, Nakahara K, Grogan L, Liewehr D, Steinberg S, Kirsch I. Genetic testing in families with hereditary nonpolyposis colorectal cancer. Arch Intern Med. 2003;163(5):573–82.CrossRefPubMedGoogle Scholar
  40. 40.
    Hall MA, McEwen JE, Barton JC, Walker AP, Howe EG, Reiss JA, Power TE, Ellis SD, Tucker DC, Harrison BW, McLaren GD, Ruggiero A, Thomson EJ. Concerns in a primary care population about genetic discrimination by insurers. Genet Med. 2005;7(5):311–6.CrossRefPubMedGoogle Scholar
  41. 41.
    Hall MA, Rich SS. Genetic privacy laws and patients’ fear of discrimination by health insurers: the view from genetic counselors. Am Soc Law Med Ethics. 2000;28:245–57.CrossRefGoogle Scholar
  42. 42.
    Hamburg M, Collins F. The path to personalized medicine. New Engl J Med. 2010;363:301–4.CrossRefPubMedGoogle Scholar
  43. 43.
    Hess PG, Preloran HM, Browner CH. Diagnostic genetic testing for fatal illness: the experience of patients with movement disorders. New Genet Soc. 2009;28(1):3–18.CrossRefGoogle Scholar
  44. 44.
    Hoy M, Durnin M. The potential economic impact of a ban on the use of genetic information for life and health insurance. Ottawa: Office of the Privacy Commissioner of Canada; 2012.Google Scholar
  45. 45.
    Hudson K, Javitt G, Burke W, Byers P, ASHG Social Issues Committee. ASHG statement on direct-to-consumer genetic testing in the United States. Am J Hum Genet. 2007;81(3):635–7.CrossRefPubMedCentralGoogle Scholar
  46. 46.
    Huizenga CR, Lowstuter K, Banks KC, Lagos VI, Vandergon VO, Weitzel JN. Evolving perspectives on genetic discrimination in health insurance among health care providers. Fam Cancer. 2010;9(2):253–60.CrossRefPubMedGoogle Scholar
  47. 47.
    Insurance Act. R.S.O. 1990, c. I-4. Ontario, Canada. 1990.Google Scholar
  48. 48.
  49. 49.
    Joly Y, Braker M, Le Huynh M. Genetic discrimination in private insurance: global perspectives. New Genet Soc. 2010;29(4):351–68.CrossRefGoogle Scholar
  50. 50.
    Joly Y, Burton H, Knoppers BM, Ngueng Feze I, Dent T, Pashayan N, Chowdhury S, Foulkes W, Hall A, Hamet P, Kirwan N, Macdonald AS, Simard J, Van Hoyweghen I. Life insurance: genomic stratification and risk classification. Eur J Hum Genet. 2014;22:575–9.CrossRefPubMedCentralPubMedGoogle Scholar
  51. 51.
    Joly Y, Ngueng Feze I, Simard J. Genetic discrimination and life insurance: a systematic review of the evidence. BMC Med. 2013;11:25.CrossRefPubMedCentralPubMedGoogle Scholar
  52. 52.
    Keogh LA, Otlowski M. Life insurance and genetic test results: a mutation carrier's fight to achieve full cover. Med J Aust. 2013;199(5):263–6.CrossRefGoogle Scholar
  53. 53.
    Keogh LA, van Vliet CM, Studdert DM, Maskiell JA, Macrae FA, St John DJ, Gaff CL, Young MA, Southey MC, Giles G, Rosenthal DA, Hopper JL, Jenkins MA. Is uptake of genetic testing for colorectal cancer influenced by knowledge of insurance implications? Med J Aust. 2009;191(5):255–8.PubMedGoogle Scholar
  54. 54.
    Kimmich O, Bradley D, Whelan R, Mulrooney N, Reilly RB, Hutchinson S, O'Riordan S, Hutchinson M. Sporadic adult onset primary torsion dystonia is a genetic disorder by the temporal discrimination test. Brain J Neurol. 2011;134(9):2656–63.CrossRefGoogle Scholar
  55. 55.
    Kirkland SA, Raina PS, Wolfson C, Strople G, Kits O, Dukeshire S, Angus CL, Szala-Meneok K, Uniat J, Keshavarz H, Furlini L, Pelletier A. Exploring the acceptability and feasibility of conducting a large longitudinal population-based study in Canada. Can J Aging. 2009;28(3):231–42.CrossRefPubMedGoogle Scholar
  56. 56.
    Klein C, Schlossmacher MG. The genetics of Parkinson disease: implications for neurological care. Nat Clin Pract Neurol. 2006;2(3):136–46.CrossRefPubMedGoogle Scholar
  57. 57.
    Klitzman R. Exclusion of genetic information from the medical record: ethical and medical dilemmas. JAMA. 2010;304(10):1120–1.CrossRefPubMedCentralPubMedGoogle Scholar
  58. 58.
    Knoppers BM, Godard B, Joly Y. Life insurance and genetics: a comparative international overview. In: Rothstein MA, editor. Genetics and life insurance: medical underwriting and social policy. Cambridge: MIT Press; 2004. p. 173–94.Google Scholar
  59. 59.
    Knoppers BM, Joly Y, Simard J, Durocher F. The emergence of an ethical duty to disclose genetic research results: international perspectives. Eur J Hum Genet. 2006;14:1170–8.CrossRefPubMedGoogle Scholar
  60. 60.
    Laedtke AL, O'Neill SM, Rubinstein W, Vogel KJ. Family physicians’ awareness and knowledge of the genetic information non-discrimination act (GINA). J Genet Couns. 2012;21:345–52.CrossRefPubMedGoogle Scholar
  61. 61.
    Lautenbach DM, Christensen KD, Sparks JA, Green RC. Communicating genetic risk information for common disorders in the era of genomic medicine. Annu Rev Genomics Hum Genet. 2013;14:491–513.CrossRefPubMedGoogle Scholar
  62. 62.
    Lemaire J, Subramanian K, Armstrong K, Asch D. Pricing term insurance in the presence of a family history of breast or ovarian cancer. North Am Actuar J. 2000;4:75–87.CrossRefGoogle Scholar
  63. 63.
    Lemke T. “A slap in the face”. An exploratory study of genetic discrimination in Germany. Genomics Soc Policy. 2009;5(2):22–39.CrossRefGoogle Scholar
  64. 64.
    Lemke T. Perspectives on genetic discrimination. New York: Routledge; 2013.Google Scholar
  65. 65.
    Lemmens T. Can insurance law accommodate the uncertainty associated with preliminary genetic information? Can Bar Rev. 2004;83:357–410.Google Scholar
  66. 66.
    Lemmens T, Joly Y, Knoppers BM. Genetic and life insurance: a comparative analysis. GenEdit. 2004;2(2):1–15.Google Scholar
  67. 67.
    Lemmens T, Pullman D, Rodal R. Revisiting genetic discrimination issues in 2010: policy options for Canada. Ottawa: GPS; 2010.Google Scholar
  68. 68.
    Lichtenberg FR. The effect of pharmaceutical innovation on longevity: patient level evidence from the 1996–2002 medical expenditure panel survey and linked mortality public-use files. Forum Health Econ Policy. 2013;16(1):1–33.CrossRefGoogle Scholar
  69. 69.
    Lowstuter K, Sand S, Blazer KR, MacDonald DJ, Banks KC, Lee CA, Schwerin BU, Juarez M, Uman GC, Weitzel N. Influence of genetic discrimination perceptions and knowledge on cancer genetics referral practice among clinicians. Genet Med. 2008;10:691–8.CrossRefPubMedGoogle Scholar
  70. 70.
    Lynch EL, Doherty RJ, Gaff CL, Macrae FA, Linderman GJ. “Cancer in the family” and genetic testing: implications for life insurance. Med J Aust. 2003;179:480–3.PubMedGoogle Scholar
  71. 71.
    Macdonald AS. The actuarial relevance of genetic information in the life and health insurance context. Ottawa: Office of the Privacy Commissioner; 2011.Google Scholar
  72. 72.
    Macdonald AS, Yu F. The impact of genetic information on the insurance industry: conclusion from the ‘bottom-up’ modeling programme. ASTIN Bullet J Int Actuarial Assoc. 2011;41(2):343–76.Google Scholar
  73. 73.
    Malpas PJ. Is genetic Information relevantly different from other kinds of non-genetic information in the life insurance context? J Med Ethics. 2007;34:548–51.CrossRefGoogle Scholar
  74. 74.
    Matloff ET, Shappell H, Brierley K, Bernhardt BA, Mckinnon W, Peshkin BN. What would you do? Specialists’ perspectives on cancer genetic testing, prophylactic surgery, and insurance discrimination. J Clin Oncol. 2000;18(12):2484–92.PubMedGoogle Scholar
  75. 75.
    McEwen JE, McCarthy C, Reilly PR. A survey of state insurance commissioners concerning genetic testing and life insurance. Am J Hum Genet. 1992;55:785–92.Google Scholar
  76. 76.
    McEwen JE, McCarthy K, Reilly PR. A survey of medical directors of life insurance companies concerning use of genetic testing and life insurance. Am J Hum Genet. 1993;55:33–45.Google Scholar
  77. 77.
    National Health and Medical Research Council. Discussing direct-to-consumer genetic DNA testing with patients: a short guide for health professionals. 2013. Published online at (Last accessed April 1, 2015)
  78. 78.
    Meiser B, Dunn S. Psychological impact of genetic testing for Huntington’s disease: an update of the literature. J Neurol Neurosurg Psychiatry. 2000;69:574–8.CrossRefPubMedCentralPubMedGoogle Scholar
  79. 79.
    Meyer J, Westera J. Life insurance and genetic testing for prostate cancer: what advice for patients? ANZ J Surger. 2012;82(4):194–5.CrossRefGoogle Scholar
  80. 80.
    Morren M, Rijken M, Baanders A, Bensing J. Perceived genetic knowledge, attitudes towards genetic testing, and the relationship between these among patients with a chronic disease. Patient Educ Couns. 2007;65(2):197–204.CrossRefPubMedGoogle Scholar
  81. 81.
    Mouchawar J, Hensley-Alford S, Laurion S, Ellis J, Kulchak-Rahm A, Finucane ML, Meenan R, Axell L, Pollack R, Ritzwoller D. Impact of direct-to-consumer advertising for hereditary breast cancer testing on genetic services at a managed care organization: naturally-occurring experiment. Genet Med. 2005;7(3):191–7.CrossRefPubMedGoogle Scholar
  82. 82.
    Nance MA. Genetics and genetic counseling related issues. In: Frucht SJ, editor. Movement disorder emergencies: diagnosis and treatment, Current clinical neurology. 2nd ed. New York: Human Press; 2013. p. 375–84.CrossRefGoogle Scholar
  83. 83.
    Nedelcu R, Blazer KR, Schwerin BU, Gambol P, Manthat P, Uman GC, Weitzel JN. Genetic discrimination: the clinician perspective. Clin Genet. 2004;66:311–7.CrossRefPubMedGoogle Scholar
  84. 84.
    Ngueng Feze I, Joly Y. Can’t always get what you want? Try an indirect route you just might get what you need: a study on access to genetic data by Canadian life insurers. Curr Pharmacogenomics Pers Med. 2014;12:56–64.CrossRefGoogle Scholar
  85. 85.
    NHS. House of Lords Science and Technology Committee – second report on genomic medicine. London: National Health Services; 2009.Google Scholar
  86. 86.
    Nowland W. Human genetics. A rational view of insurance and genetic discrimination. Science. 2002;297(5579):195–6.CrossRefGoogle Scholar
  87. 87.
    Otlowski M. Avoiding genetic testing and insurance: an exploration of the legality and ethics of precautionary measures in anticipation of unfavorable test outcomes. Monash Bioeth Rev. 2001;20:24–32.CrossRefGoogle Scholar
  88. 88.
    Otlowski M. Genetic testing and insurance: the case for regulation. Agenda. 2002;9(4):335–54.Google Scholar
  89. 89.
    Otlowski M, Barlow-Stewart K, Taylor S, Stranger M, Trealoar S. Investigating genetic discrimination in the Australian life insurance sector: the use of genetic test results in underwriting, 1999–2003. J Law Med. 2007;14:367–96.PubMedGoogle Scholar
  90. 90.
    Otlowski M, Taylor S, Bombard Y. Genetic discrimination: international perspectives. Annu Rev Genomics Hum Genet. 2012;13:433–54.CrossRefPubMedGoogle Scholar
  91. 91.
    Pamarti AK. Genetic information nondiscrimination act (GINA) and its affects on genetic counseling practice: a survey of genetic counselors. Brandeis University, 2011.
  92. 92.
    Pasche B, Absher D. Whole-genome sequencing: a step closer to personalized medicine. JAMA J Am Med Assoc. 2011;305:1596–7.CrossRefGoogle Scholar
  93. 93.
    Peterson E, Milliron K, Lewis K, Goold S, Merajver S. Health insurance and discrimination concerns and BRCA1/2 testing in a clinic population. Cancer Epidemiol Biomarkers Prev. 2007;11:79–87.Google Scholar
  94. 94.
    Pfeffer NL, McCarthy Veach P, LeRoy BS. An investigation of genetic counselors’ discussions of genetic discrimination with cancer risk patients. J Genet Couns. 2003;12(5):419–38.CrossRefPubMedGoogle Scholar
  95. 95.
    Phoenix Strategic Perspective Inc. Survey of Canadians on privacy-related issues. Ottawa: Office of the Privacy Commissioner of Canada; 2013Google Scholar
  96. 96.
    Powell KP, Cogswell WA, Christianson CA, Dave G, Verma A, Eubanks S, Henrich V. Primary care physicians’ awareness, experience and opinions of direct-to-consumer genetic testing. J Genet Couns. 2011;21:113–26.CrossRefPubMedGoogle Scholar
  97. 97.
    Quebec Civil Code, LRQ, c C-1991.Google Scholar
  98. 98.
    Riley B, Culver J, Skrzynia C, Senter L, Peters J, Costalas J, Callif-Daley F, Grumet S, Hunt K, Nagy R, McKinnon W, Petrucilli N, Bennett R, Trepanier A. Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the national society of genetic counselors. J Genet Couns. 2012;21(2):151–61.CrossRefPubMedGoogle Scholar
  99. 99.
    Rothstein MA. Why treating genetic information separately is a bad idea. Texas Rev Law Pol. 1999;4(1):33–7.Google Scholar
  100. 100.
    Rothstein MA, Joly Y. Genetic discrimination in life insurance: contemporary issues and approaches in the global economy. In: Atkinson P, Glasner P, Lock M, editors. The handbook of genetics and society: mapping the new genomic era. London: Routledge; 2009. p. 127–44.Google Scholar
  101. 101.
    Joly Y, Kim R, Salman S, Ngueng Feze I. The use of genetic information outside of the therapeutic or health research relationship: an international perspective. In: Quinn G, De Paor A, Blanck P, editors. Genetic discrimination: transatlantic perspectives on the case for a European level legal response. New York: Routledge; 2015.Google Scholar
  102. 102.
    Scheuner MT, De Vries H, Kim B, Meili RC, Olmstead SH, Teleki S. Are electronic health records ready for genomic medicine? Genet Med. 2009;11(7):510–7.CrossRefPubMedGoogle Scholar
  103. 103.
    Schneider SA, Klein C. What is the role of genetic testing in movement disorders practice? Curr Neurol Neurosci Rep. 2011;11:351–61.CrossRefPubMedGoogle Scholar
  104. 104.
    Schneider SA, Schneider UH, Klein C. Genetic testing for neurologic disorder. Semin Neurol. 2011;31(5):542–52.CrossRefPubMedGoogle Scholar
  105. 105.
    Soini S. Genetic testing legislation in western Europe – a fluctuating regulatory target. J Community Genet. 2012;3(2):143–53.CrossRefPubMedCentralGoogle Scholar
  106. 106.
    Stefansson H, Rye DB, Hicks A, Petursson H, Ingason A, Thorgeirsson TE, Palsson S, Sigmundsson T, Sigurdsson A, Eiriksdottir I, Soebech E, Bliwise D, Beck J, Rosen A, Waddy S, Trotti L, Iranzo A, Thambisetty M, Hardarson GA, Kristjansson K, Gudmundsson L, Thorsteinsdottir U, Kong A, Gulcher JR, Gudbjartsson D, Stefansson K. A genetic risk factor for periodic limb movements in sleep. New Engl J Med. 2007;357:639–47.CrossRefPubMedGoogle Scholar
  107. 107.
    Subramanian K, Lemaire J, Hershey J, Pauly M, Armstrong K, Asch D. Estimating adverse selection costs from genetic testing for breast and ovarian cancer: the case of life insurance. J Risk Insur. 1999;66:531–50.CrossRefGoogle Scholar
  108. 108.
    Suther S, Goodson P. Barrier to the provision of genetic services by primary care physicians: a systematic review of the literature. Genet Med. 2003;5(2):70–6.CrossRefPubMedGoogle Scholar
  109. 109.
    Sweden. The Genetic Integrity Act, no. 351. 2006.Google Scholar
  110. 110.
    Trepanier A, Ahrens M, McKinnon W, Peters J, Stopfer J, Grumet SC, Manley S, Culver JO, Acton R, Larsen-Haidle J, Correia LA, Bennett R, Pettersen B, Ferlita TD, Costalas JW, Hunt K, Donlon S, Skrzynia C, Farrell C, Callif-Daley F, Walsh Vockley C, National Society of Genetic Counselors. Genetic cancer risk assessment and counseling: recommendations of the national society of genetic counselors. J Genet Couns. 2004;13(2):83–114.CrossRefPubMedGoogle Scholar
  111. 111.
    Ullman-Cullere MH, Mathew JP. Emerging landscape of genomics in the electronic health record for personalized medicine. Hum Mutat. 2011;32(5):512–6.CrossRefPubMedGoogle Scholar
  112. 112.
    Van den Berg S, Shen Y, Jones SJM, Gibson WT. Genetic counseling in direct-to-consumer exome sequencing: a case report. J Genet Couns. 2014. doi: 10.1007/s10897-014-9737-0.PubMedCentralGoogle Scholar
  113. 113.
    Van Hoyweghen I, Horstman K. European practices of genetic information and insurance: lessons for the genetic information nondiscrimination act. JAMA. 2008;300(3):326–7.CrossRefPubMedGoogle Scholar
  114. 114.
    Wade CH, Wilfond BS. Ethical and clinical practice considerations for genetic counselors related to direct-to-consumer marketing of genetic tests. Am J Med Genet. 2006;142C(4):284–92.CrossRefPubMedGoogle Scholar
  115. 115.
    Wilde A, Meiser B, Mitchell P, Schofield P. Public interest in predictive genetic testing, including direct-to-consumer testing, for susceptibility to major depression: preliminary findings. Eur J Hum Genet. 2010;18:47–51.CrossRefPubMedCentralPubMedGoogle Scholar
  116. 116.
    Zgheib NK, Arawi T, Mahfouz R, Sabra R. Attitudes of health care professionals towards pharmacogenetic testing. Mol Diagn Ther. 2011;15(2):115–22.CrossRefPubMedGoogle Scholar
  117. 117.
    Zick C, Mathews C, Roberts J, Cook-Deegan R, Pokorski R, Green RC. Genetic testing for Alzheimer’s disease and its impact on insurance purchasing behavior. Health Aff. 2005;24:483–90.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.Faculty of Medicine, Department of Human Genetics, Centre of Genomics and PolicyMcGill UniversityMontrealCanada

Personalised recommendations